New diabetes pill tested in chinese patients – early safety results expected

NCT ID NCT07073170

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new daily pill called LY3549492 in 36 Chinese adults with type 2 diabetes. The main goal was to check safety and side effects over about 18 weeks. Participants had diabetes for at least 6 months and were on diet, exercise, or stable metformin. This is a first step to see if the drug is safe enough for larger studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University First Hospital

    Dongcheng District, 100009, China

  • Peking University People's Hospital

    Beijing, 100033, China

  • West China Hospital of Sichuan University

    Chengdu, 610041, China